|Home | About | Journals | Submit | Contact Us | Français|
Hepatitis A virus (HAV), an atypical Picornaviridae that causes acute hepatitis in humans, grows poorly in cell culture and in general does not cause cytopathic effect. Foreign sequences have been inserted into different parts of the HAV genome. However, the packaging size limit of HAV has not been determined. The purpose of the present study is to investigate the maximum size of additional sequences that the HAV genome can tolerate without loosing infectivity.
In vitro T7 polymerase transcripts of HAV constructs containing a 456-nt fragment coding for a blasticidin (Bsd) resistance gene, a 1,098-nt fragment coding for the same gene fused to GFP (GFP-Bsd), or a 1,032-nt fragment containing a hygromycin (Hyg) resistance gene cloned into the 2A-2B junction of the HAV genome were transfected into fetal Rhesus monkey kidney (FRhK4) cells. After antibiotic selection, cells transfected with the HAV construct containing the resistance gene for Bsd but not the GFP-Bsd or Hyg survived and formed colonies. To determine whether this size limitation was due to the position of the insertion, a 606 bp fragment coding for the Encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES) sequence was cloned into the 5' nontranslated (NTR) region of HAV. The resulting HAV-IRES retained the EMCV IRES insertion for 1-2 passages. HAV constructs containing both the EMCV IRES at the 5' NTR and the Bsd-resistance gene at the 2A-2B junction could not be rescued in the presence of Bsd but, in the absence of antibiotic, the rescued viruses contained deletions in both inserted sequences.
HAV constructs containing insertions of approximately 500-600 nt but not 1,000 nt produced viable viruses, which indicated that the HAV particles can successfully package approximately 600 nt of additional sequences and maintain infectivity.
Hepatitis A virus (HAV), a member of the Picornaviridae family, causes acute hepatitis in humans. The 27-32 nm non-enveloped HAV icosahedral particles encapsidate a 7.5 kb single-stranded positive-sense RNA genome , which contains a long open reading frame (ORF) flanked by 5' and 3' end non-translated regions (NTR). The long 5' NTR of approximately 750 nucleotides (nt) has a complex structure and contains an internal ribosome entry site (IRES) required for viral translation. The 3' NTR is short and ends in a poly(A) tail . The HAV long ORF encodes a polyprotein of approximately 250 kDa that undergoes co- and post-translational processing into smaller structural (VP0, VP3, and VP1-2A) and non-structural (2B, 2C, 3A, 3B, 3C, and 3D) proteins [3,4]. HAV 3C is a cysteine proteinase (3Cpro) responsible for most of the polyprotein cleavages and is the only protease coded in the HAV genome [5-9]. The 2A-2B junction is the primary cleavage site of the HAV polyprotein processed by 3Cpro [9,10]. The VP0 undergoes structural cleavage, and an unknown host cellular protease cleaves the VP1-2A junction .
HAV is a hepatotropic virus transmitted through the fecal-oral route. Pathogenesis of HAV is poorly understood, and it is unclear whether the virus needs to replicate in extra-hepatic sites before reaching the liver. After binding to its cellular receptor HAVCR1 [12,13], the HAV genome is delivered to the cytoplasm by an unknown mechanism. Once in the cytoplasm, the HAV genome is translated, transcribed, and encapsidated without in general causing cytopathic effect. The virus is eliminated by the immune system and does not establish chronic infection. Inactivated HAV vaccines are safe and effective, and are currently used in most of the world to prevent and treat HAV infection [1,14,15].
Considerable interest has been devoted to develop HAV as an expression vector for combination vaccines, expression of proteins in the liver, and basic research on this poorly understood human pathogen. We have previously shown that replication-competent HAV constructs containing inserts of 60-81 nt coding for malaria and FLAG-tag epitopes at the N-terminus of the HAV polyprotein were stable for at least 6 passages . An HAV recombinant containing 420-nt insertion at the 2A-2B junction was stable for up to five passages . HAV constructs carrying a seven amino acid human immunodeficiency virus gp41 epitope at the surface of the HAV particles elicited an immune response against gp41 in infected animals [17,18]. Recently, we showed that a 456-nt fragment coding for a blasticidin (Bsd) resistant gene inserted at the 2A-2B junction of wild type HAV was stable for 9 passages , conferred Bsd resistance to infected cells, and was used to develop an antibiotic resistance titration assay to evaluate anti-HAV antibodies in preparations of human immunoglobulins . Although foreign sequences have been successfully inserted into different parts of the HAV, the packaging size limit of HAV has not been determined. To study the maximum size of foreign sequences that HAV could tolerate, we cloned exogenous sequences into the 2A-2B junction and/or N-terminus of the polyprotein. A 456-nt fragment coding for a Bsd resistance gene was engineered into the 2A-2B junction of HAV and maintained for 25 passages with or without antibiotic selection. A recombinant HAV containing the Encephalomyocarditis (EMCV) internal ribosome entry site (IRES) of 606 nt cloned at the 5'NTR between the HAV IRES and the initiation codon of the HAV polyprotein only maintained the insert for a few passages. However, recombinant HAV constucts containing approximately 1,000 nt at the 2A-2B junction or both the EMCV IRES at the 5'NTR and the Bsd resistance gene at the 2A-2B junction could not be rescued from transfected cells. Our results indicated that HAV has a restricted packaging size limit that can accommodate approximately 600 nt of additional sequences.
To determine the packaging size limit of the HAV genome, we inserted foreign sequences into a 66-nt polylinker engineered between 3Cpro cleavage sites at the 2A-2B junction of the HAV cDNA in pHAVvec9  (Figure (Figure1).1). A 396-nt fragment containing a Bsd resistance gene coding for a Bsd deaminase, a 1098-nt fragment coding for the same resistance gene fused to the GFP protein (GFP-Bsd), or a 1032-nt fragment containing a hygromycin (Hyg) resistance gene coding for a hygromycin-phosphotransferase were inserted into the polylinker of pHAVvec9, and termed pHAVvec9-Bsd, pHAVvec9-GFP-Bsd, and pHAVvec9-Hyg, respectively (Figure (Figure1).1). All the inserts lacked translation initiation and termination codons to allow expression of the coded proteins as part of the HAV polyprotein. To rescue viruses, T7 polymerase in vitro transcripts of the HAV constructs were transfected into FRhK4 cells. A day after transfection, cells were split 1:6 and grown in medium that contained Bsd 0.5-3 μg/ml or hygromycin 25-250 μg/ml. As expected, some cells transfected with transcripts from pHAVvec9-Bsd survived selection with 1 μg/ml Bsd and developed colonies (Figure (Figure2A).2A). However, cells transfected with the T7 in vitro transcripts from pHAVvec9-GFP-Bsd did not survive antibiotic selection, show GFP fluorescence, or produce infectious virus even without Bsd selection. Cells transfected with in vitro transcripts from pHAVvec9-Hyg also did not survive antibiotic selection. A virus stock termed HAVvec9-Bsd was prepared from these Bsd-resistant cells and used to infect naïve FRhK4 cells in the presence of 2 μg/ml Bsd. Cells infected with HAVvec9-Bsd but not mock-infected cells survived selection with Bsd, indicating that HAVvec9-Bsd was infectious. However, HAVvec9-Bsd produced 1-1.5 log less virus than HAVvec9 and parental HAV/7 . The stability of Bsd gene in HAVvec9-Bsd virus was assessed during 25 serial passages in the absence of Bsd. RT-PCR (Figure (Figure2B)2B) and nucleotide sequence analysis (data not shown) revealed that the Bsd gene insert was stable during the 25 serial passages in FRhK4 cells. These data suggested that HAV could tolerated insertions of approximately 500-1,000 nt at the 2A-2B junction
To assess whether the packaging size limitation of 500-1,000 nt was site-specific, we inserted a nt fragment into the 5' NTR of the HAV genome between the HAV IRES and the initiation codon of the HAV polyprotein. We chose the EMCV IRES because it is a strong ribosome entry site compared to the weak HAV IRES [21,22] and has been widely used in other viral systems [23-29]. We hypothesized that a virus with both IRESes would have a translation advantage compared to the HAV IRES alone. The EMCV IRES 606-nt fragment was cloned adjacent to the polyprotein initiation codon to assure that it would drive translation of the HAV polyprotein (Figure (Figure3).3). FRhK4 cells were transfected with T7 transcripts of the double IRES HAV construct. After two weeks of incubation, IF analysis revealed that 10% of the cells had the characteristic cytoplasmic granular fluorescence of HAV-infected cells compared to 100% of the cells transfected with pHAVvec9 or HAVvec9-Bsd transcripts (Figure (Figure4A).4A). A virus stock was prepared and termed HAV-IRES, and the presence of the EMCV IRES was assessed by RT-PCR analysis (Figure (Figure4B).4B). To do so, viral particles were purified by sedimentation through a 40% sucrose cushion, and viral RNA was extracted from the pellet. As a negative control, the same amount of transfected T7 RNA transcripts (20 μl) was purified in parallel by sedimentation through a 40% sucrose cushion, and RNA was extracted from the pellet. As a positive RT-PCR control, we used RNA extracted from purified HAV/7 particles. RT-PCR analysis showed that the HAV-IRES but not HAV/7 particles contained the expected 600 nt EMCV IRES fragment, which was verified by automated nucleotide sequencing. RT-PCR fragments were not amplified from the negative control sample. These data indicated that the 606-nt EMCV IRES insert was packaged into the HAV-IRES particles. To further assess the stability of the inserted EMCV-IRES, we performed serial passages of HAV-IRES in FRhK4 cells at weekly intervals. At each cell passage, a virus stock was produced and analyzed by RT-PCR as described above. After 2 passages, most of the EMCV IRES was deleted leaving only a small insert of 21 nt (data not shown). These data indicated that HAV was capable of packaging the 606-nt insert coding for the EMCV IRES but that HAV-IRES was an unstable recombinant virus.
To rule out that constrains at the specific insertion sites unrelated to packaging limited the viability of the HAV constructs, we cloned both the Bsd resistance gene into the 2A-2B junction and the EMCV IRES into the 5' NTR (Figure (Figure5).5). T7 polymerase in vitro transcripts of the resulting construct, pHAVvec9-Bsd-IRES, were transfected into FRhK4 cells. Transfected cells did not survive selection 1 μg/ml Bsd indicating that HAV did not tolerate the double insertion. IF analysis of transfected cells grown in the absence of Bsd selection showed that less than 10% of cells contained HAV antigens (data not shown). RT-PCR analysis of RNA extracted from particles purified by sedimentation through a 40% sucrose cushion revealed that the EMCV IRES and the Bsd resistance gene contained deletions (Figure (Figure6).6). Nucleotide sequence analysis of PCR fragments showed the presence of only 21 nt from the EMCV IRES at the 5'NTR and 120 nt from the Bsd resistance gene at 2A-2B junction. Interestingly, the polylinker, 3Cpro cleavage sites, and Gly hinge flanking sequences were preserved. These data indicated that HAV cannot tolerate insertions larger than 600 nucleotides, and that this limitation in size is not due to site-specific restrictions of the inserted sequences.
In this paper we studied the packaging size limit of HAV. The virus tolerated the insertion of approximately 500 nt at the 2A-2B junction and 600 nt at the 5'NTR. The insertion of 456-nt fragment coding for a Bsd resistance gene flanked by 3Cpro cleavage sites was remarkably stable for 25 passages even in the absence of antibiotic. However, HAV could not accommodate larger inserts in the same site, and viruses containing GFP-Bsd and Hyg selectable markers could not be rescued from transfected cells. It should be pointed out FRhk4 cells transfected with eukaryotic expression vectors containing the GFP-Bsd and Hyg resistance genes survived selection with Bsd and Hyg, respectively. Moreover, FRhK4 cells transfected with an eukaryotic expression vector containing the GFP-Bsd fusion protein fluoresced similarly to cells transfected with a construct containing only GFP (data not shown). Since HAVvec9-Bsd was very stable, it is unclear why we could not rescue an HAV construct containing GFP-Bsd. One simple explanation is that we exceeded the packaging size limit of HAV. However, cells transfected with pHAVvec9-GFP-Bsd in vitro transcripts did not survive selection with Bsd suggesting that packaging alone was not the only factor affecting infectivity. Therefore, we hypothesized that site-specific or sequence-specific constraints at the 2A-2B junction site prevented HAV replication. To test this hypothesis, we introduced a completely different sequence at another site of the HAV genome. To that effect, we cloned a 606-nt fragment coding for the EMCV IRES between the HAV IRES and the initiation codon of the HAV polyprotein. Because HAV containing the EMCV IRES was unstable and tended to delete the insert in a few passages, we limited our study to viruses produced at the initial passage. The failure to rescue virus from the construct containing the Bsd resistance gene at the 2A-2B junction and the EMCV IRES at the 5'NTR indicated that the maximum size of foreign sequences that can be incorporated into the HAV genome of a viable virus is approximately 600 nt. Our study showed that HAV can package genomes of approximately 8,100 nt composed of the full-length genome and an insertion of approximately 600 nt, which can accommodate an additional 200 amino acid protein into the HAV polyprotein. Although the size of the extra sequences is somehow limited, HAV could be used as an expression vector for the development of combination vaccines and delivery of genes to the liver.
In this study we showed that viable HAV can package full-length viral genomes containing insertions of approximately 600 nt.
Fetal rhesus monkey kidney (FRhK4) cells, a gift of S. Emerson, National Institutes of Health (NIH), were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. The cell culture-adapted human HM-175 strain of HAV was derived from an infectious cDNA clone , termed HAV/7 , and grown in FRhK-4 cells. Nucleotide positions of the HAV genome are according to the published HM175 HAV cDNA sequence .
Standard molecular biology methods  were used to construct the HAV recombinants. PCR-based DNA fragments were amplified using expand high fidelity PCR kit (Roche) in 25 cycles consisting of 95°C for 30 sec, 55°C for 1 min, and 72°C for 2-3 min. For overlap PCR, DNA fragments were denatured at 94°C and annealed at 45°C for 2 min in each step. The blasticidin (Bsd), fusion of green fluorescent protein with Bsd (GFP-Bsd), and hygromycin (Hyg) resistance genes were generated by PCR with eliminating the translation initiation (ATG) and termination codons and introducing 5' SalI and 3' KpnI restriction sites for cloning into the polylinker at the 2A-2B junction of the HAV polyprotein in pHAVvec9 . To clone inserts in-frame at the 2A-2B junction, PCR products and pHAVvec9 were digested with SalI and KpnI, gel purified, and ligated. The oligonucleotides used to generate the PCR fragments are described in Table Table1.1. The sequences inserted into the HAV geome are described in Table Table2.2. Constructs were verified by automated nucleotide sequence analysis. The following plasmids were used in this work:
pT7HAV contains the infectious cDNA cell culture-adapted HM-175 strain of HAV under the control of a T7 RNA polymerase promoter in pGEM1, and the in vitro transcripts were infectious in FRhK4 cells .
pHAVvec9 was derived from pT7HAV as described previously . pHAVvec9 contains a polylinker with unique SalI, SnaBI, and KpnI restriction sites.
pHAVvec9-Bsd contains Bsd gene cloned into the polylinker of the HAV cDNA in pHAVvec9 .
pHAVvec9-GFP-Bsd contains a GFP-Bsd fusion cloned into the HAV cDNA polylinker in pHAVvec9. The GFP-Bsd fusion was amplified by PCR from pTracer-CMV/Bsd (Invitrogen). To create unique SalI site in GFP-Bsd insert, a silent substitution mutation (from GTCGAC to GTAGAC) was introduced to eliminate SalI site in the GFP gene sequence using overlap PCR.
pHAVvec9-Hyg contains a Hyg resistance gene cloned into the HAV cDNA polylinker in pHAVvec9. The Hyg resistance gene was amplified by PCR from pCFB-EGSH (Stratagene).
pHAV-IRES contains the EMCV IRES (corresponding to 278-836 nt of the EMCV genome) cloned between the HAV IRES and the HAV polyprotein initiation codons in pT7HAV (Figure (Figure3).3). To construct pHAV-IRES, a 606-nt cDNA fragment containing nt 278-836 of EMCV flanked at the 5' end by a XbaI site and at the 3'end by the two tandem initiation codons of the HAV polyprotein and an XbaI restriction site was amplified from pCITE-1 (Novagen), a plasmid containing the EMCV IRES. This amplified cDNA fragment was cut with XbaI and cloned into the unique XbaI site adjacent to the HAV initiation codons in pT7HAV.
pHAVvec9-Bsd-IRES was constructed by cloning the EMCV IRES from pHAV-IRES into pHAVvec9-Bsd. To do so, the 1,783-nt BspEI and BstEII fragment of pHAV-IRES containing the EMCV IRES was cloned into pHAVvec9-Bsd cut with BspEI and BstEII at nts 24 and 1194 of the HAV cDNA, respectively. The resulting construct contained both the EMCV IRES and the 5'NTR and the Bsd resistance gene at the 2A-2B junction of the HAV cDNA.
Synthesis of full-length HAV RNA transcripts was performed using T7 RNA polymerase . To do so, plasmids were linearized with HaeII, which cuts immediately downstream of the poly(A) of the HAV cDNA [16,30]. Subconfluent FRhK4 cells in 25-cm2 flasks were transfected with in vitro synthesized RNA transcripts using DEAE-dextran as facilitator  or Lipofectamine 2000 (Invitrogen). After 30 min incubation at room temperature, fresh media was added to replace transfection solution and incubated at 35°C. Cells were split weekly into new flasks, and an aliquot was passed to 8-well chamber slides for immunofluorescence (IF) analysis. To prepare viral stocks, monolayers with approximately 80% of the cells expressing HAV antigens as assessed by IF analysis were subjected to three freeze-thaw cycles and clarified by low-speed centrifugation. Supernatants containing the virus stocks were stored at -70°C.
FRhK4 cells were grown in 8-well Permanox chamber slides (Nunc, Inc.) at 35°C in a CO2 incubator for 24-48 h. Cell culture media was aspirated and the cells were fixed with cold acetone for 30 min at -20°C. Fixed cell monolayers were air-dried, blocked with PBS-2% FBS at room temperature, and stained with a mix of anti-HAV neutralizing murine monoclonal antibodies K2-4F2 and K3-2F2  and fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse antibody (KPL, Inc). Stained slides were air-dried, coverslips were mounted with PermaFluor aqueous medium (Shandon Immunon, PA), and fluorescent micrographs were taken with a Zeiss Axioscope microscope at 400× magnification.
RNA was extracted from HAV particles using QIAamp viral RNA mini kit (Qiagen). RT-PCR was carried out using the Superscript-II enzyme kit (Invitrogen). The cDNA was synthesized with primers corresponding to HAV nt position 3715-3738 or 1167-1194. PCR fragments were amplified using primers corresponding to HAV nts 2928-2951 and 3715-3738 or 484-507 and 1167-1194. Amplified DNA fragments were gel purified, and sequenced using the ABI Prism BigDye terminator cycle-sequencing ready reaction kit (Applied Biosystems) and with ABI Prism (model 3100) analyzer (Applied Biosystems).
The authors declare that they have no competing interests.
The findings and conclusions in this article have not been formally disseminated by the Food and Drug Administration and should not be construed to represent any Agency determination or policy.
KK and GGK conceived the study. KK and GGK designed the experiments and drafted the manuscript. KK and SMN performed the experiments.
We thank Susan Zullo for critical review of the manuscript. The work was supported by FDA intramural funding to GGK. This project was supported in part by the appointment of SMN to the Research Participation Program at the Center for Biologics Evaluation and Research administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the U.S. Food and Drug Administration. All authors read and approved the final manuscript.